ENT

Your Article Summary

See Latest Articles

Beta-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: A companion analysis of the TAX 324 trial
Journal of Clinical Oncology, 11/25/09

Cullen JK et al. – Increased tumor expression of T-II is strongly associated with adverse outcome in LASCCHN patients treated with IC, and our data suggest low expression of T-II may predict patients most likely to benefit from induction TPF therapy. Further, simple models which combine expression of T-II with a carefully defined set of additional immunohistochemical markers may have significant prognostic impact for patients with LASCCHN.

• Pretherapy biopsy specimens available for 265 of 501 participants
• Expression of a series of six markers (p53, thymidylate synthase, glutathione s-transferase pi [GST-], Bcl 2, &beta tubulin II [T-2], and HER2 neu) evaluated by immunohistochemistry

• For patients with low T-II expression, median OS was 58.6 months (95% CI, not reached [NR]), compared with 18.2 months for patients with high T-II expression (95% CI, 13.11 to 30.06: hazard ratio [HR], 2.39; 95% CI, 1.67 to 3.72)
• PFS in patients with low T-II expression 43.2 months (95% CI, 24.4 to NR) versus 9.8 months (95% CI, 7.06 to 18.53) for high T-II expression, with a HR of 1.9 (95% CI, 1.43 to 2.77; P < .0001). The predictive value of T-II expression was greater in TPF versus PF arm than in PF arm

Today in Head and Neck...keeping you current

Receive free subspecialty "5-minute updates" via email

Tonsillectomy in post-transplant lymphoproliferative disease in children
The Laryngoscope, 02/09/10

Analysis of hearing preservation after endolymphatic mastoid sac surgery for Meniere's disease
The Laryngoscope, 02/09/10

Associations of tonsillar hypertrophy and snoring with history of wheezing in childhood
Pediatric Pulmonology, 02/09/10

 See all of Head and Neck